Thromboresistant-anticoagulant extracellular matrix
US-2017360992-A1 · Dec 21, 2017 · US
US11045581B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11045581-B2 |
| Application number | US-201716461461-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 17, 2017 |
| Priority date | Nov 18, 2016 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are inks including decellularized extracellular matrix (dECM) particles and scaffolds made from the inks. Also provided are methods of making the scaffolds and applications for the scaffolds. In an embodiment, a porous scaffold comprises dECM particles and an elastomer, wherein the scaffold is planar having a thickness of about 100 μm or greater, the scaffold comprises irregularly shaped pores having a random orientation and distribution throughout the scaffold, and the scaffold is free of crosslinking between the molecular components of the scaffold.
Opening claim text (preview).
What is claimed is: 1. A porous scaffold consisting essentially of: decellularized extracellular matrix (dECM) particles and an elastomer; wherein the scaffold is planar having a thickness of about 100 μm or greater; wherein the scaffold comprises irregularly shaped pores having a random orientation and distribution throughout the scaffold; wherein the scaffold is free of crosslinking between the molecular components of the scaffold and is not a gel; wherein the scaffold is substantially free of liquid; wherein the scaffold is mechanically robust enough to retain its structural integrity while undergoing cutting and multiple foldings in surgical applications, wherein retaining its structural integrity comprises not breaking, crumbling, flaking or tearing; and wherein the porous scaffold is sized and configured for use with cells, a tissue, or an organ. 2. The scaffold of claim 1 , wherein the scaffold is a monolithic, continuous structure. 3. The scaffold of claim 1 , wherein the scaffold, in a dry state, exhibits a Young's modulus in the range of from about 1 MPa to about 30 MPa. 4. The scaffold of claim 1 , wherein the scaffold, in a dry state, exhibits an ultimate tensile strength of from about 0.1 MPa to about 1.5 MPa. 5. The scaffold of claim 1 , wherein the scaffold exhibits an absorbency in the range of from about 100% to about 500%. 6. The scaffold of claim 1 , the scaffold having from about 30% to about 80% by weight dECM particles, based on the total solids content of the scaffold, and from about 20% to about 70% by weight elastomer, based on the total solids content of the scaffold. 7. The scaffold of claim 1 , wherein the scaffold is capable of supporting a population of human mesenchymal stem cells, hepatocytes or ovarian follicles, the population which retains its viability over a time period of at least 28 days when the scaffold is cultured in vitro. 8. The scaffold of claim 1 , wherein the scaffold is capable of supporting ovarian tissue which retains its viability over a time period of at least 8 weeks and is capable of supporting the development of one or more vasa-positive oocytes from the ovarian tissue, when the scaffold is cultured in vitro. 9. The scaffold of claim 8 , wherein the dECM particles are derived from an ovary. 10. The scaffold of claim 1 , wherein the scaffold is capable of supporting muscle tissue which retains its viability over a time period of at least 6 weeks when the scaffold is implanted in a mammalian subject in vivo. 11. The scaffold of claim 10 , wherein the dECM particles are derived from muscle, liver, heart, kidney, uterus, skin, or collagen. 12. The scaffold of claim 1 , the scaffold having an external topography that is complementary to a pattern mold.
Materials specially adapted for additive manufacturing · CPC title
using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions · CPC title
with macromolecular fillers · CPC title
Porous materials, {e.g. foams or sponges} · CPC title
for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.